Red Bear Angels portfolio company TETmedical, Inc. has reached a pivotal regulatory milestone: the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its NSE-FAST® (Neuron Specific Enolase — Functional Activity Stroke Test), a rapid blood assay designed to aid in the diagnosis of acute ischemic stroke. The designation was issued on June 15, 2026, by the FDA's Center for Devices and Radiological Health.
Stroke is one of the leading causes of death and long-term disability in the United States, affecting approximately 840,000 Americans each year — roughly 87% of which are ischemic in nature. Despite the urgency, ischemic stroke is the number one condition associated with serious misdiagnosis-related harm in emergency medicine, with an estimated 17% of cases missed. NSE-FAST® addresses this gap by measuring the functional enzymatic activity of Neuron Specific Enolase (NSE) in a patient's blood plasma, providing clinicians with a rapid, near-patient diagnostic tool to complement existing imaging.
The FDA Breakthrough Devices Program accelerates the development and review of technologies that address unmet needs in life-threatening conditions. With this designation, TETmedical gains prioritized access to FDA experts and enhanced opportunities for regulatory alignment as it prepares to launch a multi-center pivotal study in Q4 2026. The company anticipates completing patient enrollment in the second half of 2027 and submitting its marketing application by Q4 2027.
